CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 416 enrolled
Drug / intervention
IL-YANG FLU Vaccine Prefilled Syringe INJ. +1 morebiological
Likely dose
IL-YANG FLU Vaccine Prefilled Syringe INJ. 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02263131
NCT02263131Phase 3Completed
CompareCT.gov

Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.

Il-Yang Pharm. Co., Ltd.·interventional·Posted Oct 13, 2014·Updated Jul 9, 2020

In Brief

A Phase 3 clinical trial evaluating IL-YANG FLU Vaccine Prefilled Syringe INJ. and VAXIGRIP Prefilled Syringe INJ. for Healthy. Completed, enrolled 416 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single intramuscular injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 13, 2014
Enrollment StartOct 1, 2013
Primary CompletionJan 1, 2014
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.7 years ago

Interventions

IL-YANG FLU Vaccine Prefilled Syringe INJ.biological

IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL

VAXIGRIP Prefilled Syringe INJ.biological

VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL